Por favor, use este identificador para citar o enlazar este ítem: https://observatoriovacunascovid19.unam.mx/jspui/jspui/handle/123456789/7
Título : SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Autor : Tian, Jing-Hui
Patel, Nita
Haupt, Robert
Zhou, Haixia
Weston, Stuart
Hammond, Holly
Logue, James
Portnoff, Alyse D.
Norton, James
Guebre-Xabier, Mimi
Zhou, Bin
Jacobson, Kelsey
Maciejewski, Sonia
Khatoon, Rafia
Wisniewska, Malgorzata
Moffitt, Will
Kluepfel-Stahl, Stefanie
Ekechukwu, Betty
Papin, James
Boddapati, Sarathi
Wong, C. Jason
Piedra, Pedro A.
Frieman, Matthew B.
Massare, Michael J.
Fries, Louis
Lövgren Bengtsson, Karin
Stertman, Linda
Ellingsworth, Larry
Glenn, Gregory
Smith, Gale
Palabras clave : vacunas
vaccines
NVX-CoV2373
Novavax
inmunogenicidad
seguridad
estudios preclínicos
vacunas de subunidades
Fecha de publicación : 14-Jan-2021
Editorial : Springer Nature Limited
Citación : Nature Communications 2021;12:372.
Resumen : The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) from the full-length spike (S) protein that is stable in the prefusion conformation. NVX-CoV2373 S form 27.2-nm nanoparticles that are thermostable and bind with high affinity to the human angiotensin-converting enzyme 2 (hACE2) receptor. In mice, low-dose NVX-CoV2373 with saponin-based Matrix-M adjuvant elicit high titer anti-S IgG that blocks hACE2 receptor binding, neutralize virus, and protects against SARS-CoV-2 challenge with no evidence of vaccine-associated enhanced respiratory disease. NVX-CoV2373 also elicits multifunctional CD4+ and CD8+ T cells, CD4+ follicular helper T cells (Tfh), and antigen-specific germinal center (GC) B cells in the spleen. In baboons, low-dose levels of NVX-CoV2373 with Matrix-M was also highly immunogenic and elicited high titer anti-S antibodies and functional antibodies that block S-protein binding to hACE2 and neutralize virus infection and antigen-specific T cells. These results support the ongoing phase 1/2 clinical evaluation of the safety and immunogenicity of NVX-CoV2373 with Matrix-M (NCT04368988).
URI : https://www.nature.com/articles/s41467-020-20653-8
https://observatoriovacunascovid19.unam.mx/jspui/jspui/handle/123456789/7
Aparece en las colecciones: Artículos científicos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Portada 2.png174.8 kBimage/pngVisualizar/Abrir


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.